Landos Biopharma, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q1 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Landos Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q1 2024.
  • Landos Biopharma, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 15.9 %, a 29.5% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2024 15.9 +3.62 +29.5% Mar 31, 2024
Q4 2023 11.9 -5.2 -30.4% Dec 31, 2023
Q3 2023 11.3 -7.57 -40.2% Sep 30, 2023
Q2 2023 10.8 -6.73 -38.3% Jun 30, 2023
Q1 2023 12.3 -4.31 -26% Mar 31, 2023
Q4 2022 17.1 +3.95 +30.1% Dec 31, 2022
Q3 2022 18.9 +0.94 +5.25% Sep 30, 2022
Q2 2022 17.6 Jun 30, 2022
Q1 2022 16.6 Mar 31, 2022
Q4 2021 13.1 Dec 31, 2021
Q3 2021 17.9 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.